104 related articles for article (PubMed ID: 18724534)
1. Weekly docetaxel regimens and radiation pneumonitis.
Mauri D; Tzachanis D; Tsekoura P; Xanthakis I; Tsali L; Roumbkou S; Fountzilas G
J Support Oncol; 2008; 6(6):265-6. PubMed ID: 18724534
[No Abstract] [Full Text] [Related]
2. Erosive conjunctival and corneal inflammatory changes in a patient receiving weekly docetaxel for breast cancer.
Chalvatzis N; Manthou ME; Tzamalis A; Hytiroglou P; Dimitrakos S
Ocul Immunol Inflamm; 2014 Apr; 22(2):164-6. PubMed ID: 23876214
[No Abstract] [Full Text] [Related]
3. Bi-weekly docetaxel in the adjuvant treatment of node-positive or high-risk breast cancer patients: phase I study of the Shiga Breast Cancer Study Group.
Abe H; Ogawa H; Okino T; Kato M; Sako H; Sano H; Shimomatsuya T; Suwa H; Higashide S
Breast Cancer; 2009; 16(1):37-41. PubMed ID: 18493840
[TBL] [Abstract][Full Text] [Related]
4. Weekly low-dose docetaxel-based chemoradiotherapy for locally advanced oropharyngeal or hypopharyngeal carcinoma: a retrospective, single-institution study.
Fukada J; Shigematsu N; Takeda A; Ohashi T; Tomita T; Shiotani A; Kunieda E; Kawaguchi O; Fujii M; Kubo A
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):417-24. PubMed ID: 19409727
[TBL] [Abstract][Full Text] [Related]
5. Flagellate erythema induced by docetaxel.
Tallon B; Lamb S
Clin Exp Dermatol; 2008 May; 33(3):276-7. PubMed ID: 18201264
[TBL] [Abstract][Full Text] [Related]
6. Fatal hypersensitivity pneumonitis associated with docetaxel.
Gurram MK; Pulivarthi S; McGary CT
Tumori; 2013; 99(3):e100-3. PubMed ID: 24158075
[TBL] [Abstract][Full Text] [Related]
7. Weekly docetaxel in metastatic breast cancer patients: no superior benefits compared to three-weekly docetaxel.
Schröder CP; de Munck L; Westermann AM; Smit WM; Creemers GJ; de Graaf H; Stouthard JM; van Deijk G; Erjavec Z; van Bochove A; Vader W; Willemse PH
Eur J Cancer; 2011 Jun; 47(9):1355-62. PubMed ID: 21251813
[TBL] [Abstract][Full Text] [Related]
8. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial.
Nuzzo F; Morabito A; De Maio E; Di Rella F; Gravina A; Labonia V; Landi G; Pacilio C; Piccirillo MC; Rossi E; D'Aiuto G; Thomas R; Gori S; Colozza M; De Placido S; Lauria R; Signoriello G; Gallo C; Perrone F; de Matteis A
Crit Rev Oncol Hematol; 2008 May; 66(2):171-80. PubMed ID: 18160303
[TBL] [Abstract][Full Text] [Related]
9. Low-dose weekly docetaxel is as tolerable as pemetrexed in previously treated advanced non-small-cell lung cancer.
Chung FT; Lee KY; Fang YF; Shieh MH; Lin SM; Yu CT; Lo YL; Lin TY; Kuo CH; Feng PH; Ni YL; Kuo HP
Chemotherapy; 2011; 57(2):147-55. PubMed ID: 21454972
[TBL] [Abstract][Full Text] [Related]
10. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
Mathew P; Thall PF; Jones D; Perez C; Bucana C; Troncoso P; Kim SJ; Fidler IJ; Logothetis C
J Clin Oncol; 2004 Aug; 22(16):3323-9. PubMed ID: 15310776
[TBL] [Abstract][Full Text] [Related]
11. A prospective, open label, randomized phase II trial of weekly docetaxel versus weekly vinorelbine as first line chemotherapy in patients with androgen independent prostate cancer.
Krainer M; Tomek S; Elandt K; Horak P; Albrecht W; Eisenmenger M; Höltl W; Schramek P; Stackl W; Zielinski C; Reibenwein J
J Urol; 2007 Jun; 177(6):2141-5; discussion 2145. PubMed ID: 17509302
[TBL] [Abstract][Full Text] [Related]
12. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
[TBL] [Abstract][Full Text] [Related]
13. [Radiation pneumonitis: Pathophysiology and treatment].
Hayakawa K; Yanaihara H
Nihon Rinsho; 2002 May; 60 Suppl 5():546-9. PubMed ID: 12101733
[No Abstract] [Full Text] [Related]
14. Safety and efficacy of trastuzumab every 3 weeks combined with cytotoxic chemotherapy in patients with HER2-positive recurrent breast cancer: findings from a case series.
Ardavanis A; Tryfonopoulos D; Orfanos G; Karamouzis M; Scorilas A; Alexopoulos A; Rigatos G
Onkologie; 2005 Nov; 28(11):558-64. PubMed ID: 16249641
[TBL] [Abstract][Full Text] [Related]
15. A phase II study of weekly docetaxel in patients with anthracycline pretreated metastatic breast cancer.
Ford HE; Yap YS; Miles DW; Makris A; Hall M; Miller L; Harries M; Smith IE; Johnston SR
Cancer Chemother Pharmacol; 2006 Dec; 58(6):809-15. PubMed ID: 16528527
[TBL] [Abstract][Full Text] [Related]
16. Lethal pneumonitis after docetaxel chemotherapy: case report and review of the literature.
Storaas E; Holmaas G; Gravdal K; Børretzen A; Eikesdal HP
Acta Oncol; 2013 Jun; 52(5):1034-8. PubMed ID: 23244676
[No Abstract] [Full Text] [Related]
17. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
18. Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer.
Nakamura T; Fuwa N; Takayama K; Inokuchi H; Tomoda T; Takada A; Makita C; Shiomi M; Yokouchi J; Watanabe K
Head Neck; 2012 Nov; 34(11):1634-9. PubMed ID: 22179897
[TBL] [Abstract][Full Text] [Related]
19. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer.
Rivera E; Mejia JA; Arun BK; Adinin RB; Walters RS; Brewster A; Broglio KR; Yin G; Esmaeli B; Hortobagyi GN; Valero V
Cancer; 2008 Apr; 112(7):1455-61. PubMed ID: 18300256
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of weekly docetaxel in patients with recurrent or metastatic endometrial cancer: AGO Uterus-4.
Günthert AR; Ackermann S; Beckmann MW; Camara O; Kiesel L; Rensing K; Schröder W; Steiner E; Emons G;
Gynecol Oncol; 2007 Jan; 104(1):86-90. PubMed ID: 16996111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
